Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers Stock Surges 69.2% in Three Months: What's Next?
12:05pm, Thursday, 30'th Jan 2025
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Hims & Hers Health, Inc. (HIMS) Increases Despite Market Slip: Here's What You Need to Know
06:50pm, Wednesday, 29'th Jan 2025
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $31.86, signifying a +1.01% move from its prior day's close.
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
02:26am, Wednesday, 29'th Jan 2025
I anticipate the FDA will soon declare the semaglutide shortage resolved, potentially slowing Hims' revenue growth rate due to compounding restrictions. I foresee explosive revenue growth post-FDA ann
Is Hims & Hers Health Stock a Buy?
05:10am, Tuesday, 28'th Jan 2025
Established in 2017, Hims & Hers Health (HIMS -1.17%) is a relatively young company addressing age-old healthcare challenges by offering prescription medications, over-the-counter products, and person
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
06:51pm, Wednesday, 22'nd Jan 2025
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $29.72, signifying a -0.3% move from its prior day's close.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Tuesday, 21'st Jan 2025
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Ready To Outperform Further
10:00am, Monday, 20'th Jan 2025
Hims & Hers Health is a rapidly growing telehealth leader with a unique, customer-focused business model, demonstrated by its aggressive customer base expansion and accelerating revenue growth momentu
Hims & Hers Health: A Stock to Trade or Own?
07:00am, Monday, 20'th Jan 2025
Hims & Hers Health Inc. NYSE: HIMS, a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, especially over the past year. The stock climbed an astounding 215% in 2024,
Hims & Hers Health: The Market Is Likely Wrong
03:14pm, Sunday, 19'th Jan 2025
Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA's negative outlook contrasts with Hims' projected 90%
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
11:37am, Friday, 17'th Jan 2025
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treatin
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
08:15am, Friday, 17'th Jan 2025
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Is Hims & Hers Stock in Trouble?
06:22am, Thursday, 16'th Jan 2025
Hims & Hers Health (HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth company has been growing at a fast rate, making it one of the best stocks t
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
06:51pm, Monday, 13'th Jan 2025
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $25.90, moving +1.93% from the previous trading session.
Hims & Hers Stock Is Poised for a Major Surge in 2025
11:30am, Friday, 10'th Jan 2025
Hims & Hers (HIMS -4.02%) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the stock. But the business is about much more than just one product, and Trav
Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
08:39am, Thursday, 09'th Jan 2025
Hims & Hers capitalizes on telehealth growth in hair, mental, sexual health, and weight loss. Yet, limited product differentiation, reliance on branding, and FDA risks weaken its long-term moat. Forec
